For research use only. Not for therapeutic Use.
MM11253 is a potent and selective RARγ antagonist with an IC50 of 44 nM. MM11253 has lower inhibition of RARα, RARβ and RXRα. MM11253 blocks the growth inhibitory effects of RARγ-selective agonists[1][3].
MM11253 blocks the ability of MM11254 and MM11389 to inhibit squamous cell carcinoma cell growth[2].
| Catalog Number | I008117 |
| CAS Number | 345952-44-5 |
| Synonyms | 6-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dithiolan-2-yl]naphthalene-2-carboxylic acid |
| Molecular Formula | C28H30O2S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C28H30O2S2/c1-26(2)11-12-27(3,4)24-17-22(9-10-23(24)26)28(31-13-14-32-28)21-8-7-18-15-20(25(29)30)6-5-19(18)16-21/h5-10,15-17H,11-14H2,1-4H3,(H,29,30) |
| InChIKey | DPVGXUNWCVEIGT-UHFFFAOYSA-N |
| SMILES | CC1(CCC(C2=C1C=CC(=C2)C3(SCCS3)C4=CC5=C(C=C4)C=C(C=C5)C(=O)O)(C)C)C |
| Reference | [1]. M I Dawson, et al. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC i [2]. Q Le, et al. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene. 2000 Mar 9;19(11):1457-65. |
